Efficacy and Safety of Botulinum Toxin vs. Placebo in Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Major depressive disorder (MDD) is a serious mental disorder that represents a substantial public health problem. Several trials have been undertaken to investigate the role of botulinum toxin type A (BTX-A) in the treatment of MDD, but the conclusions were controversial. To examine the...
Main Authors: | Huan Qian, Fangjie Shao, Cameron Lenahan, Anwen Shao, Yingjun Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-12-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2020.603087/full |
Similar Items
-
Treatment of Depression with Botulinum Toxin
by: Marc Axel Wollmer, et al.
Published: (2022-05-01) -
A Systematic Review and Meta-Analysis of Efficacy of Botulinum Toxin A for Neuropathic Pain
by: Anupam Datta Gupta, et al.
Published: (2022-01-01) -
Recombinant botulinum toxin as a new stage in the development of botulinum toxin therapy. Possibilities and perspectives of use in neurological practice
by: R. K. Shikhkerimov, et al.
Published: (2022-12-01) -
Botulinum toxin in aesthetic medicine [electronic resource]: /
by: 391545 Maio, Mauricio de, et al.
Published: (2007) -
The Use of Botulinum Toxin in Medicine: Safety and Efficacy Based on the Latest Research
by: Anna Jaremek, et al.
Published: (2023-08-01)